^
    7ms
    HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer. (PubMed, Mol Carcinog)
    COS7 cells transiently transfected with the HER3-V104L mutation in the presence of HER binding partners showed higher expression of p-HER3, p-ERK1/2 versus HER3-WT in a NRG-independent manner without any change in AKT signaling. Overall, this study shows the clinical relevance of the HER3 V104L and the V104M mutations and its response to HER2, PI3K and ERK inhibitors.
    Journal
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    HER-2 mutation • HER-2 expression • ERBB3 expression • ERBB3 mutation • ERBB3 V104L • ERBB3 V104M
    over1year
    ERBB3 and BRAF Mutations as Potential Biomarkers in Non-Small Cell Lung Cancer Patients Under Immunotherapy-Based Treatments (IASLC-WCLC 2023)
    Molecular profiling of liquid biopsies at baseline identified alterations that could impact on patient outcomes. Our data suggest that the presence of BRAF pathogenic variants may be a good prognostic factor in stage IV NSCLC patients treated with immunotherapy or chemo-immunotherapy, while pathogenic mutations in ERBB3 could be a biomarker of high risk of disease progression. Additional studies analyzing larger cohorts of patients are needed to clarify these hypotheses.
    Clinical • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    BRAF V600E • BRAF mutation • BRAF V600 • BRAF wild-type • ERBB3 mutation • BRAF T599 • ERBB3 V104M
    |
    Oncomine™ Pan-Cancer Cell-Free Assay